Your browser is no longer supported. Please, upgrade your browser.
Settings
MRUS Merus N.V. daily Stock Chart
MRUS [NASD]
Merus N.V.
Index- P/E- EPS (ttm)-2.55 Insider Own11.40% Shs Outstand28.95M Perf Week1.35%
Market Cap404.42M Forward P/E- EPS next Y-2.51 Insider Trans10.34% Shs Float25.45M Perf Month-17.91%
Income-64.60M PEG- EPS next Q-0.60 Inst Own76.00% Short Float0.89% Perf Quarter-15.98%
Sales28.70M P/S14.09 EPS this Y-79.30% Inst Trans0.78% Short Ratio2.06 Perf Half Y-4.04%
Book/sh3.96 P/B3.60 EPS next Y-8.30% ROA- Target Price23.46 Perf Year9.45%
Cash/sh7.54 P/C1.89 EPS next 5Y- ROE- 52W Range10.19 - 20.95 Perf YTD1.21%
Dividend- P/FCF- EPS past 5Y-13.20% ROI-44.80% 52W High-31.98% Beta0.82
Dividend %- Quick Ratio6.30 Sales past 5Y88.60% Gross Margin- 52W Low39.90% ATR1.46
Employees87 Current Ratio6.30 Sales Q/Q-28.40% Oper. Margin- RSI (14)48.33 Volatility9.54% 10.12%
OptionableNo Debt/Eq0.00 EPS Q/Q-88.10% Profit Margin- Rel Volume2.21 Prev Close14.25
ShortableYes LT Debt/Eq0.00 EarningsApr 01 BMO Payout- Avg Volume110.72K Price14.25
Recom1.60 SMA20-3.97% SMA505.46% SMA200-9.70% Volume0 Change0.00%
May-27-20Downgrade RBC Capital Mkts Outperform → Sector Perform $16
Nov-20-19Resumed Guggenheim Buy
Jun-28-19Initiated ROTH Capital Buy $20
Apr-12-19Resumed Guggenheim Buy
Apr-03-19Upgrade RBC Capital Mkts Sector Perform → Outperform
Mar-27-19Initiated Berenberg Buy $35
Jan-02-18Downgrade RBC Capital Mkts Outperform → Sector Perform
Sep-15-17Initiated RBC Capital Mkts Outperform $28
Mar-21-17Downgrade Citigroup Buy → Neutral
Dec-22-16Upgrade Citigroup Neutral → Buy
Nov-07-16Downgrade Citigroup Buy → Neutral
Jun-13-16Initiated Wedbush Outperform $14
Jun-13-16Initiated Guggenheim Buy
Jun-13-16Initiated Citigroup Buy
May-15-20 08:09AM  Volatility 101: Should Merus (NASDAQ:MRUS) Shares Have Dropped 28%? Simply Wall St.
May-14-20 09:05AM  Merus Announces the Acceptance of Six Abstracts at Upcoming Medical Conferences and Provides Program Updates GlobeNewswire -7.05%
May-11-20 07:15PM  Merus NV (MRUS) Reports Q1 Loss, Misses Revenue Estimates Zacks
04:36PM  Merus Announces Financial Results for the First Quarter and Provides Business Update GlobeNewswire
Mar-16-20 07:15AM  We Think Merus (NASDAQ:MRUS) Can Afford To Drive Business Growth Simply Wall St. -24.52%
06:37AM  Merus N.V. Analysts Are Cutting Their Estimates: Here's What You Need To Know Simply Wall St.
Mar-12-20 04:01PM  Merus Announces Financial Results for the Fourth Quarter and Full Year 2019 and Provides Business Update GlobeNewswire -16.92%
Jan-09-20 08:59AM  ImmunoPrecise Subsidiary Joins Genmab and Merus in Expansion to new Biotech Accelerator at the Center of Europe's Most Competitive Science Region CNW Group
Dec-16-19 08:30AM  Merus Announces Chief Executive Officer Transition GlobeNewswire
06:12AM  Hedge Funds Have Never Been This Bullish On Merus N.V. (MRUS) Insider Monkey
Nov-15-19 10:47AM  Merus N.V. Just Reported Earnings, And Analysts Cut Their Target Price Simply Wall St.
Nov-12-19 06:15PM  Merus N.V. (MRUS) Reports Q3 Loss, Tops Revenue Estimates Zacks
04:01PM  Merus Announces Financial Results for the Third Quarter 2019 and Provides Business Update GlobeNewswire
10:42AM  Can European Buyouts Aid Canopy Growth's (CGC) Q2 Earnings? Zacks
Nov-11-19 11:24AM  Can Cannabis Therapy Drive Canopy Growth's (CGC) Q2 Earnings? Zacks
Nov-06-19 04:54PM  Hedge Funds Have Never Been More Bullish On Merus N.V. (MRUS) Insider Monkey
Nov-05-19 08:32AM  Merus Announces Pricing of Public Offering of Common Shares GlobeNewswire
Nov-04-19 04:54PM  Merus N.V. Announces Proposed Underwritten Public Offering of Common Shares GlobeNewswire -7.19%
Oct-27-19 11:50AM  Merus Bispecific Antibody MCLA-128 Shows Encouraging Early Clinical Activity in Patients with Cancers Harboring NRG1 Gene Fusions GlobeNewswire
Oct-25-19 11:05AM  Merus Announces Presentation and Poster on MCLA-128 and MCLA-129 Programs at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics GlobeNewswire +15.63%
Sep-20-19 09:42AM  We Think Merus (NASDAQ:MRUS) Can Afford To Drive Business Growth Simply Wall St.
Aug-19-19 05:15PM  Merus N.V. (MRUS) Reports Q2 Loss, Misses Revenue Estimates Zacks +10.29%
04:01PM  Merus Announces Financial Results for the Second Quarter 2019 and Provides Business Update GlobeNewswire
Aug-02-19 10:53AM  Acorda (ACOR) Q2 Earnings and Revenues Surpass Estimates Zacks
Jul-23-19 07:59AM  Moving Average Crossover Alert: Merus Zacks
Jul-18-19 11:18AM  NuCana Initiates Dosing in Phase I Study for Solid Tumors Zacks
10:33AM  Will Merus N.V. (MRUS) Report Negative Q2 Earnings? What You Should Know Zacks
Jul-11-19 11:19AM  Moleculin Files New Patents for Cancer Candidate Annamycin Zacks
09:10AM  Moving Average Crossover Alert: Merus Zacks
Jul-09-19 09:54AM  Inovio Ends Enrollment in Vulvar Dysplasia Study on VGX-3100 Zacks
Jun-26-19 06:11AM  Nabriva Gets EMA Acceptance for Pneumonia Drug Lefamulin Zacks
Jun-24-19 10:05AM  Vertex's (VRTX) Symdeko Gets FDA Nod for Use in Children Zacks
Jun-21-19 03:47PM  Should Merus (NASDAQ:MRUS) Be Disappointed With Their 75% Profit? Simply Wall St.
Jun-20-19 12:42PM  Can We See Significant Institutional Ownership On The Merus N.V. (NASDAQ:MRUS) Share Register? Simply Wall St. -7.60%
09:35AM  Akari (AKTX) Eye Candidate Proves Safety in Early-Stage Study Zacks
08:33AM  Merus N.V. (MRUS) Shares March Higher, Can It Continue? Zacks
Jun-19-19 09:40AM  Intrexon Up on Striking 100M Cannabinoid Deal With Surterra Zacks +9.24%
Jun-10-19 06:06PM  Athenex Rallies on Positive Early Data on Psoriasis Candidate Zacks
Jun-06-19 10:29AM  Reata's (RETA) Kidney Candidate Gets Orphan Drug Status Zacks
Jun-03-19 08:28AM  Merus to Present at the Jefferies 2019 Healthcare Conference GlobeNewswire
May-30-19 04:05PM  Merus Announces Financial Results for the First Quarter 2019 and Provides Business Update GlobeNewswire
May-23-19 08:34AM  Should You Worry About Merus N.V.'s (NASDAQ:MRUS) CEO Pay? Simply Wall St.
08:00AM  Merus Announces 2019 Annual General Meeting of Shareholders GlobeNewswire
May-20-19 08:38AM  Merus to Present at the RBC Capital Markets 2019 Healthcare Conference GlobeNewswire -5.90%
May-16-19 10:49AM  Agios' Tibsovo Meets Endpoint in Cholangiocarcinoma Study Zacks +6.79%
May-15-19 11:07AM  Mallinckrodt Ends Enrollment in Phase III for Terlipressin Zacks
May-11-19 02:36AM  Tilray (TLRY) to Report Q1 Earnings: What's in the Cards? Zacks
May-10-19 03:45PM  Tilray (TLRY) to Report Q1 Earnings: What's in the Cards? Zacks
May-09-19 08:00AM  Merus Announces First Patient Treated in Phase 1 Clinical Trial of MCLA-145 for Advanced Solid Tumors GlobeNewswire
May-08-19 11:39AM  Evoke Pharma (EVOK) to Post Q1 Earnings: What's in Store? Zacks
May-03-19 10:19AM  Agios (AGIO) Earnings and Revenues Surpass Estimates in Q1 Zacks
May-02-19 11:44AM  Acorda (ACOR) Earnings and Revenues Beat Estimates in Q1 Zacks
May-01-19 11:46AM  Vertex (VRTX) Q1 Earnings and Revenues Surpass Estimates Zacks
Apr-26-19 02:04PM  BioMarin (BMRN) Shares Down Despite Q1 Earnings & Sales Beat Zacks
Apr-17-19 10:46AM  Kamada to Begin Phase III Study for Inhaled AAT Product in 2H Zacks -8.13%
Apr-16-19 10:59AM  Fibrocell Out-licenses Skin Disease Gene Therapy, Stock Rises Zacks
Apr-15-19 10:50AM  Mallinckrodt (MNK) Completes Enrollment in Skin Tissue Study Zacks +11.75%
06:13AM  Will Merus Continue to Surge Higher? Zacks
Apr-03-19 04:00PM  Merus Announces Financial Results for the Full Year 2018 and Provides Business Update GlobeNewswire
Apr-01-19 07:00AM  Merus and Incyte Present MCLA-145 Program Preclinical Data at the AACR Annual Meeting 2019 GlobeNewswire -6.77%
Mar-11-19 08:09AM  Merus to Present at the Cowen & Co. 39th Annual Health Care Conference GlobeNewswire
Feb-07-19 07:00AM  Merus to Participate in Guggenheim Healthcare Talks Idea Forum GlobeNewswire
Jan-29-19 10:11AM  Vertex's Kalydeco Wins Health Canada Nod to Treat CF in Kids Zacks
Jan-25-19 07:00AM  Johnson & Johnson Is Selling These 2 Biotech Stocks Barrons.com
Jan-07-19 10:06AM  Amarin Down on Lower '19 View, Posts Preliminary '18 Results Zacks +8.12%
07:00AM  Merus Announces IND Clearance for MCLA-145 GlobeNewswire
Jan-03-19 04:03AM  ProBioGen's GlymaxX® ADCC Enhancement Technology Used by Betta Pharmaceuticals CNW Group -6.01%
Jan-02-19 08:00AM  Merus Announces Strategic Collaboration with Betta Pharmaceuticals to Develop and Commercialize MCLA-129 in China GlobeNewswire
Dec-28-18 07:29AM  The Daily Biotech Pulse: Opko Settles With SEC, Obalon Inks Financing Deals, Harpoon Files For IPO Benzinga +7.27%
Dec-27-18 05:05PM  Merus Announces Financial Results for the Third Quarter 2018 and Provides Business Update GlobeNewswire
Dec-20-18 04:45PM  Merus Announces Global Settlement and End to All Patent Litigation with Regeneron Pharmaceuticals GlobeNewswire -8.19%
Dec-18-18 10:08AM  Is Merus N.V. (MRUS) Going to Burn These Hedge Funds? Insider Monkey
Nov-28-18 02:39PM  Is Merus NV (NASDAQ:MRUS) A Financially Sound Company? Simply Wall St.
Nov-22-18 10:30AM  Merus N.V. (MRUS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release Zacks
Nov-08-18 07:00AM  Merus to Present at the Jefferies 2018 London Healthcare Conference GlobeNewswire +5.59%
Oct-19-18 09:20AM  Report: Developing Opportunities within Spotify Technology SA, Vornado Realty Trust, Merus N.V, Teekay Tankers, PagSeguro Digital, and Liberty Oilfield Services Future Expectations, Projections Moving into 2018 GlobeNewswire -5.26%
Sep-27-18 04:00PM  Merus to Present at the Cantor Fitzgerald Global Healthcare Conference GlobeNewswire
07:00AM  Merus Strengthens Team with Key Appointments GlobeNewswire
Aug-30-18 07:00AM  Merus to Participate in Citis 13th Annual Biotech Conference GlobeNewswire
Aug-22-18 07:00AM  Merus Announces Formation of a Scientific Advisory Board GlobeNewswire +10.88%
Aug-21-18 07:45AM  Recent Analysis Shows DURECT, Corporacion America Airports S.A., Golden Star Resources, MacroGenics, Merus N.V., and Superior Uniform Group Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Aug-10-18 08:35AM  Merus Announces Financial Results for the Second Quarter 2018 & Mid-year Operating Results GlobeNewswire
Aug-07-18 07:00AM  Merus to Present at the 2018 Wedbush PacGrow Healthcare Conference GlobeNewswire
Jul-26-18 07:06AM  Merus N.V. : Merus Announces Recent Corporate Developments and Financial Results for the First Quarter 2018 GlobeNewswire
07:00AM  Merus Announces Recent Corporate Developments and Financial Results for the First Quarter 2018 GlobeNewswire
Jul-05-18 04:01AM  Merus Announces Annual Meeting of Shareholders GlobeNewswire
04:00AM  Merus Announces Annual Meeting of Shareholders GlobeNewswire
Jun-06-18 08:20AM  Analysis: Positioning to Benefit within China Biologic Products, Merus N.V, Adient, G1 Therapeutics, Westport Fuel, and AppFolio Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
May-31-18 07:01AM  Merus to Present at the Jefferies 2018 Healthcare Conference GlobeNewswire
07:00AM  Merus to Present at the Jefferies 2018 Healthcare Conference GlobeNewswire
May-24-18 07:01AM  Merus Announces First Patient Dosed in Phase 1 Clinical Trial of MCLA-158 in Patients with Solid Tumors GlobeNewswire
07:00AM  Merus Announces First Patient Dosed in Phase 1 Clinical Trial of MCLA-158 in Patients with Solid Tumors GlobeNewswire
May-15-18 07:01AM  Merus Announces Unique Mechanism of Action of MCLA-128 That Potently Blocks HER3 Signaling Published in Cancer Cell GlobeNewswire
07:00AM  Merus Announces Unique Mechanism of Action of MCLA-128 That Potently Blocks HER3 Signaling Published in Cancer Cell GlobeNewswire
May-03-18 07:30AM  Blog Exposure - VIVUS to Acquire Janssen Pharmas PANCREAZE(R) Capsules in the United States and Canada ACCESSWIRE
Apr-26-18 07:01AM  Merus Announces Recent Corporate Developments and Financial Results for the Fourth Quarter and Full Year 2017 GlobeNewswire
06:30AM  Merus N.V. to Host Earnings Call ACCESSWIRE
Apr-19-18 07:01AM  Merus to Report Full Year 2017 Financial Results and Corporate Developments on April 26, 2018 GlobeNewswire
07:00AM  Merus to Report Full Year 2017 Financial Results and Corporate Developments on April 26, 2018 GlobeNewswire
Mar-20-18 07:01AM  Merus and the Vall d'Hebron Institute of Oncology Announce Research Collaboration to Develop Innovative Bispecific Antibodies for Therapeutic Applications in the Treatment of Cancer GlobeNewswire
Merus N.V., a clinical-stage immuno-oncology company, engages in developing bispecific antibody therapeutics. Its bispecific antibody candidate pipeline includes MCLA-128, which is in a Phase II clinical trial for the treatment of patients with metastatic breast cancer; and Phase I/II clinical trial for the treatment of gastric and non-small cell lung cancers. The company is also developing MCLA-117 that is in Phase I clinical trial for the treatment of patients with acute myeloid leukemia; and MCLA-158, which is in a Phase I clinical trial for the treatment of solid tumors with an initial focus on colorectal cancer. In addition, its research and development stage bispecific antibody candidates include MCLA-129, which is being developed in collaboration with Betta Pharmaceuticals Co. Ltd; MCLA-145, which is being developed in collaboration with Incyte Corporation; and clinical programs to explore new potential combination therapies or indication. The company was founded in 2003 and is headquartered in Utrecht, the Netherlands.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Throsby MarkEVP & Chief Scientific OfficerMay 06Sale14.543685,35144,835May 11 08:00 AM
Liu HuiEVP, CBO & Head of Merus USMay 01Option Exercise0.00582053,279May 05 04:00 PM
de Kruif JohnSVP & Chief Technology OfficerMay 01Option Exercise0.0079011,886May 05 04:00 PM
Bakker LexSVP, Chief Development OfficerMay 01Option Exercise0.0010804,315May 05 04:00 PM
Throsby MarkEVP & Chief Scientific OfficerMay 01Option Exercise0.00708045,203May 05 04:00 PM
Throsby MarkEVP & Chief Scientific OfficerApr 02Sale10.933684,02244,495Apr 06 04:00 PM
Liu HuiEVP, CBO & Head of Merus USApr 01Option Exercise0.00582052,697Apr 03 04:00 PM
Throsby MarkEVP & Chief Scientific OfficerApr 01Option Exercise0.00708044,863Apr 03 04:00 PM
Bakker LexSVP, Chief Development OfficerApr 01Option Exercise0.0010804,207Apr 03 04:00 PM
de Kruif JohnSVP & Chief Technology OfficerApr 01Option Exercise0.0079011,807Apr 03 04:00 PM
Throsby MarkEVP & Chief Scientific OfficerMar 04Sale18.103686,66144,155Mar 10 05:00 PM
Liu HuiEVP, CBO & Head of Merus USMar 02Option Exercise0.00582052,115Mar 04 05:00 PM
de Kruif JohnSVP & Chief Technology OfficerMar 02Option Exercise0.0079011,728Mar 04 05:00 PM
Throsby MarkEVP & Chief Scientific OfficerMar 02Option Exercise0.00708044,523Mar 04 05:00 PM
Bakker LexSVP, Chief Development OfficerMar 02Option Exercise0.0010804,099Mar 04 05:00 PM
Throsby MarkEVP & Chief Scientific OfficerFeb 24Sale17.7457,0881,012,74143,815Feb 26 09:17 PM
de Kruif JohnSVP & Chief Technology OfficerFeb 18Sale18.981,26824,06711,649Feb 20 05:00 PM
Bakker LexSVP, Chief Development OfficerFeb 03Option Exercise0.0010803,991Feb 04 05:00 PM
Throsby MarkEVP & Chief Scientific OfficerFeb 03Option Exercise0.00708013,282Feb 04 05:00 PM
Liu HuiEVP, CBO & Head of Merus USFeb 03Option Exercise0.00582051,533Feb 04 05:00 PM
de Kruif JohnSVP & Chief Technology OfficerFeb 03Option Exercise0.0079010,695Feb 04 05:00 PM
BVF PARTNERS L P/IL10% OwnerJan 16Buy16.15278,7304,501,4901,804,105Jan 21 05:21 PM
BVF PARTNERS L P/IL10% OwnerJan 13Buy14.9883,9621,257,6161,657,663Jan 15 06:32 PM
de Kruif JohnSVP & Chief Technology OfficerJan 02Option Exercise0.0079010,616Jan 06 05:00 PM
Bakker LexSVP, Chief Development OfficerJan 02Option Exercise0.0010803,883Jan 06 05:00 PM
Liu HuiEVP, CBO & Head of Merus USJan 02Option Exercise0.00582050,951Jan 06 05:00 PM
Throsby MarkEVP & Chief Scientific OfficerJan 02Option Exercise0.00708012,574Jan 06 05:00 PM